Cnidium monnieri for Health & Longevity - Quick Reference Sheet

Cnidium monnieri for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A dried East Asian fruit with a two-thousand-year record, mostly used as a skin wash. Human evidence covers only multi-herb creams and washes for eczema and psoriasis, with modest improvement. Bone and erection claims rest on cells and rodents. Set against sun-sensitising compounds, a liver signal, slowed drug clearance, and undeclared prescription drugs in most sexual-performance products tested. (Full Review)

Protocol

Traditional oral dose
3–10 g dried fruit daily
As a decoction, split into two doses with food. No dose has been validated in a controlled human trial.
Traditional external protocol
15–30 g of fruit in water
Decocted wash, sitz bath, or fumigation once or twice daily to affected skin; the form with the most human trial support. Best applied at night.
Extract equivalents
250–500 mg 10:1 capsule
A 500 mg 10:1 capsule approximates 5 g of raw fruit; osthole-standardized extracts run 10–98% purity.
Time to effect
Topical itch relief
1–2 weeks
Antipruritic effects appeared within 1–2 weeks in the dermatology trials.
Bone effects
A quarter at minimum
No human time-course exists; rodent bone effects required more than two months.

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Active liver disease or transaminases above twice the upper limit of normal
  • Child-Pugh Class B or C cirrhosis
  • Nitrates and nitric oxide donors (nitroglycerin, isosorbide, amyl nitrite)
  • Photosensitivity disorders (systemic lupus erythematosus, porphyria, xeroderma pigmentosum) or a history of melanoma
  • Warfarin without access to regular international normalised ratio testing
  • Within two weeks of scheduled surgery
Key Interactions
  • Warfarin and other CYP2C9 substrates (phenytoin, celecoxib, losartan, ibuprofen)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice)
  • CYP3A4 and CYP1A2 inducers (carbamazepine, rifampicin, St John's wort, tobacco smoke)
  • Antihypertensives and other vasodilators (amlodipine, doxazosin, hydralazine, sildenafil)
  • Photosensitising medications (amiodarone, doxycycline, thiazide diuretics, retinoids, methoxsalen)
  • Over-the-counter medications (ibuprofen, naproxen, high-dose paracetamol)
  • Supplements with additive effects (St John's wort, bergamot, grapefruit; fish oil, ginkgo, high-dose vitamin E; beetroot, citrulline, arginine)
  • Horny goat weed, yohimbine, and tribulus
  • Psoralen-ultraviolet-A phototherapy or medical tanning

Risk & Side Effects

  • Medium: Phototoxic skin reactions from furanocoumarins; undeclared prescription drugs in Cnidium-containing sexual-performance products
  • Low: Liver injury from osthole metabolic activation; interference with drugs cleared by CYP2C9; local irritation from topical preparations
  • Speculative: Additive blood pressure lowering; hormonal and reproductive effects; increased bleeding tendency from platelet inhibition

Monitoring

Marker Target Why
ALT <25 U/L (men), <20 U/L (women) Detects liver-cell injury, the main internal hazard
AST <25 U/L Confirms an ALT rise is hepatic rather than muscular
GGT <20 U/L (men), <15 U/L (women) Most sensitive early marker of drug-induced liver stress
INR 2.0–3.0 if anticoagulated; otherwise 0.9–1.1 Catches over-anticoagulation from CYP2C9 inhibition
25-hydroxyvitamin D 40–60 ng/mL Any bone effect is contingent on adequate vitamin D
Serum CTX 0.20–0.40 ng/mL Tracks bone resorption, the process osthole suppresses in rodents
P1NP 25–50 μg/L Tracks bone formation, the other half of the bone claim
Seated blood pressure 110–125 / 70–80 mmHg Detects additive hypotension from the vasodilatory coumarins

Cadence: Liver panel, seated blood pressure and, where the goal is bone, a bone turnover panel with vitamin D at baseline; liver enzymes and blood pressure at 6 weeks, then at 12 weeks; clotting time at 1 and 4 weeks for those anticoagulated; bone turnover markers no sooner than 6 months; every 6–12 months thereafter for continued use.

Qualitative Assessment

  • Skin itch intensity and lesion extent, scored weekly on a simple 0–10 scale where the goal is dermatological
  • Any stinging, redness, or blistering at a topical application site, particularly after daylight exposure
  • Erectile firmness and consistency, where that is the goal, recorded as a weekly rather than per-occasion impression
  • Energy levels, appetite, and right-upper-quadrant discomfort, which together precede laboratory evidence of liver strain
  • Unexplained bruising, prolonged bleeding from minor cuts, or dark stools, which flag the anticoagulant interaction
  • Light-headedness on standing, the earliest symptom of additive blood pressure lowering